NasdaqGM:PRCTMedical Equipment
Assessing PROCEPT BioRobotics (PRCT) Valuation After Mixed Q1 2026 Results And Share Price Weakness
Why PROCEPT BioRobotics (PRCT) is back in focus
PROCEPT BioRobotics (PRCT) is drawing attention after reporting first quarter 2026 results, with sales of US$83.13 million alongside a net loss of US$31.64 million and a basic loss per share of US$0.56.
See our latest analysis for PROCEPT BioRobotics.
The earnings release has landed against a weak share price backdrop, with the latest share price at US$24.63 and a year to date share price return of 19.93% decline alongside a 1 year total...